Sana Biotechnology (NASDAQ:SANA) Issues Earnings Results

Sana Biotechnology (NASDAQ:SANA) announced its earnings results on Friday. The company reported ($0.25) EPS for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.01, Zacks reports.

Sana Biotechnology Stock Down 3.8 %

SANA stock traded down $0.11 during trading on Monday, reaching $2.89. The company’s stock had a trading volume of 1,981,002 shares, compared to its average volume of 2,151,145. The company’s fifty day moving average is $4.21 and its 200-day moving average is $5.77. The company has a market capitalization of $642.93 million, a P/E ratio of -2.29 and a beta of 1.44. Sana Biotechnology has a 1 year low of $2.76 and a 1 year high of $12.00.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on SANA. JMP Securities lowered Sana Biotechnology from an “outperform” rating to a “market perform” rating in a research note on Tuesday, November 5th. Citigroup upped their price target on Sana Biotechnology from $8.00 to $15.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $8.00 price objective on shares of Sana Biotechnology in a research note on Monday.

Insider Activity

In related news, Director Richard Mulligan sold 150,000 shares of the stock in a transaction dated Tuesday, September 24th. The stock was sold at an average price of $4.08, for a total transaction of $612,000.00. Following the completion of the sale, the director now owns 2,848,121 shares in the company, valued at approximately $11,620,333.68. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 31.10% of the company’s stock.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.